US Biosimilars Market "Worth $11bn by 2020", Says Report

August 14, 2015

August 14, 2015.

The US biosimilars market will be worth $11bn by 2020 and biosimilars will account for 4% to 10% of the biologics market total by 2020, according to ReportsnReports' Global & USA Biosimilar Market Analysis to 2021.
With the expected patent expiration of twelve biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market. By 2019, 50% of the biologics market will belong to off-patent drugs, states the report, with the top five biologics targeted by biosimilar developers being Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.

http://www.reportsnreports.com/reports/411918-global-usa-biosimilar-market-analysis-to-2021-biobetters-erythropoietin-epo-human-growth-hormone-hgh-granulocyte-colony-stimulating-factor-g-csf.html

Related Content:

Technology